- Alternative id - ERM 62646-A
- Interventions - Drug: Nafamostat Mesilate|Biological: Hyperimmune Globulin|Drug: Enoxaparin|Drug: Dalteparin|Drug: Tinzaparin
- Study type - Interventional
- Study results - No Results Available
- Locations - Calvary Public Bruce Hospital, Bruce, Australian Capital Territory, Australia|The Canberra Hospital, Canberra, Australian Capital Territory, Australia|Armidale Hospital, Armidale, New South Wales, Australia|Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia|Blacktown Hospital, Blacktown, New South Wales, Australia|Campbelltown Hospital, Campbelltown, New South Wales, Australia|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|The Sutherland Hospital, Caringbah, New South Wales, Australia|Coffs Harbour Health Campus, Coffs Harbour, New South Wales, Australia|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Northern Beaches Hospital, Frenchs Forest, New South Wales, Australia|Griffith Base Hospital, Griffith, New South Wales, Australia|Hornsby Ku-Ring Gai Hospital, Hornsby, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|John Hunter Hospital, New Lambton Heights, New South Wales, Australia|Orange Health Service, Orange, New South Wales, Australia|Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Wagga Wagga Base Hospital, Wagga Wagga, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Royal Darwin Hospital, Tiwi, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Gold Coast University Hospital, Southport, Queensland, Australia|Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Ballarat Health Services, Ballarat Central, Victoria, Australia|St John of God Ballarat Hospital, Ballarat, Victoria, Australia|Bendigo Health, Bendigo, Victoria, Australia|Eastern Health (Box Hill Hospital), Box Hill, Victoria, Australia|Monash Health, Clayton, Victoria, Australia|Northern Health, Epping, Victoria, Australia|St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Frankston Hospital - Penninsula Health, Frankston, Victoria, Australia|Peninsula Private Hospital, Frankston, Victoria, Australia|Barwon Health - University Hospital Geelong, Geelong, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Cabrini Health, Malvern, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Epworth Richmond, Richmond, Victoria, Australia|Goulburn Valley Health, Shepparton, Victoria, Australia|Western Health, St Albans, Victoria, Australia|Latrobe Regional Hospital, Traralgon, Victoria, Australia|West Gippsland Hospital, Warragul, Victoria, Australia|Albury Wodonga Health, Wodonga, Victoria, Australia|Rockingham General Hospital, Cooloongup, Western Australia, Australia|Joondalup Health Campus, Joondalup, Western Australia, Australia|Armadale Health Service, Mount Nasura, Western Australia, Australia|Fiona Stanley Hospita, Murdoch, Western Australia, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|St John of God Subiaco Hospital, Subiaco, Western Australia, Australia
- Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 2400
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Death from any cause or requirement of new intensive respiratory support (invasive or non-invasive ventilation) or vasopressor/inotropic support.|Time to clinical recovery|WHO 8-point ordinal outcome scale|All-cause mortality|Days alive and free of hospital|Days alive and free of invasive or non-invasive ventilation|Shortness of breath|Quality of life|Antiviral domain-specific outcome: Viral clearance|Antiviral domain-specific outcome: Viral load|Antiviral domain-specific outcome: Safety (Liver enzymes)|Antiviral domain-specific outcome: Safety (potassium)|Antiviral domain-specific outcome: Safety (sodium)|Antiviral domain-specific outcome: Safety (bleeding)|Antiviral domain-specific outcome: Safety (thrombophlebitis)|Antiviral domain-specific outcome: serious adverse reactions|Antibody domain-specific outcome: Serious treatment-related adverse events|Antibody domain-specific outcome: Haemolysis|Antibody domain-specific outcome: Confirmed arterial thrombosis|Antibody domain-specific outcome: Confirmed venous thrombosis|Anticoagulation domain-specific outcome: Confirmed deep venous thrombosis|Anticoagulation domain-specific outcome: Confirmed pulmonary embolus|Anticoagulation domain-specific outcome: Confirmed acute myocardial infarction|Anticoagulation domain-specific outcome: Confirmed ischemic cerebrovascular event|Anticoagulation domain-specific outcome: Major bleeding|Anticoagulation domain-specific outcome: Clinically relevant non-major bleeding|Anticoagulation domain-specific outcome: Heparin-induced thrombocytopenia (HIT)|Anticoagulation domain-specific outcome: Other confirmed thrombotic event
|
